There was an increased risk of breast cancer-specific mortality in women with ER+ disease who had higher pre-diagnosis OPG serum levels (Quintile 5 > 12.38 pM as compared to Quintile 1 ≤ 7.80 pM). This evidence concerns the gene TNFRSF11B and breast carcinoma.